Immunotherapy has prompted a paradigm shift in advanced non-small cell lung cancer
(NSCLC) treatment, by demonstrating superior efficacy to chemotherapy alone both in …

The iterative discovery in various malignancies during the past decades that a number of
aberrant tumorigenic processes and signal transduction pathways are mediated by …

Small cell lung cancer (SCLC), which accounts for 10%–15% of lung cancer cases, is an
aggressive disease characterized by rapid growth and early widespread metastasis …

Lung cancer remains the number one cause of cancer-related death worldwide. Active
cancer immunotherapy is a growing field that is included as one of the most important …

Lung cancer is the leading cause of cancer-related mortality worldwide, with non-small cell
lung cancer (NSCLC) accounting for over 85% of all cases. Until recently, chemotherapy …

Small-cell lung cancer (SCLC) accounts for 13–15% of all new lung cancer cases in the US.
The tumor has a tendency to disseminate early resulting in 80–85% of patients being …

Lung cancer causes significant morbidity and mortality in China and worldwide. In China,
lung cancer accounts for nearly one-fourth of all cancer deaths. Non-small cell lung cancer …

Importance The beneficial role of immunotherapy and the clinical relevance of current
biomarkers in non–small cell lung cancer (NSCLC) remain inconclusive; thus, appropriate …

For patients with metastatic non–small-cell lung cancer (mNSCLC), the last decade has
been characterized by critical progress that has contributed to substantially improved …

In the last decade, the treatment of non-small cell lung cancer (NSCLC) has been
revolutionized by the introduction of immune checkpoint inhibitors (ICI) directed against …